In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt<span style="white-space:nowrap;"><sup>®</sup></span>), the Nigerian Institute o...In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt<span style="white-space:nowrap;"><sup>®</sup></span>), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt<span style="white-space:nowrap;"><sup>®</sup></span>-treatment, means of ranked viral loads of the patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (-41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that -41.03%, to -38.22% in the second month;23.98% in the third month;31.76% in the fourth month and 64.12% after the fifth month.展开更多
文摘In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt<span style="white-space:nowrap;"><sup>®</sup></span>), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt<span style="white-space:nowrap;"><sup>®</sup></span>-treatment, means of ranked viral loads of the patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (-41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that -41.03%, to -38.22% in the second month;23.98% in the third month;31.76% in the fourth month and 64.12% after the fifth month.
